2026-03-16 12:03:22
Structure Therapeutics Reports Positive Phase 2 Data for Aleniglipron with Significant Weight Loss Results
Expected Stock impact: Very Positive
On March 16, 2026, Structure Therapeutics Inc. (NASDAQ: GPCR) announced positive topline data from its Phase 2 ACCESS II trial for aleniglipron, an oral small molecule GLP-1 receptor agonist aimed at treating obesity. The trial demonstrated a placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% (37 lbs) at the 240 mg dose after 44 weeks, with no evidence of weight loss plateau. These results position aleniglipron as a potentially best-in-class oral GLP-1 therapy, comparable to injectable GLP-1 receptor agonists. The study involved 85 adult participants with obesity or overweight, and the results were statistically significant with a p-value of less than 0.0001. Furthermore, the ongoing ACCESS Open Label Extension (OLE) study showed continued weight loss of up to 16.2% (40.5 lbs) at the 120 mg dose after 56 weeks. The tolerability profile of aleniglipron was consistent with the GLP-1 receptor agonist class, with low rates of adverse events leading to treatment discontinuation. The company plans to initiate Phase 3 clinical development in the second half of 2026, following a Type B End-of-Phase 2 meeting with the FDA scheduled for Q2 2026. This positive data reinforces the potential of aleniglipron to address significant unmet needs in obesity treatment, with the company emphasizing its commitment to making effective therapies accessible to a broader patient population.
